Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Indivior Share News (INDV)
INDV Share
Price
INDV Share
News
INDV Share
Chat
INDV Share
Trades2,517
INDV
Live RNS
INDV Share
Charts
INDV Broker
Ratings
INDV Directors
Deals
INDV Financial
Diary
INDV
Fundamentals
INDV Short
Positions1
INDV
Media
INDV Company
Research
INDV Company
Timeline1
- There is currently no data for INDV
Indivior News
Indivior shares tumble as group sets aside $290m for US litigation
(Sharecast News) - Shares in pharmaceuticals business Indivior tumbled early on Thursday after the group revealed it had put aside $290.0m for ongoing...
Indivior announces expiry of waiting period for Opiant purchase
(Alliance News) - Indivior PLC has announced on Monday the expiration of the waiting period relating to its USD145 million purchase of Opiant Pharmace...
LONDON MARKET CLOSE: Pharma stocks fail to lift FTSE 100 in the green
(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a ra...
Indivior targets Nasdaq listing for spring 2023 as hails Sublocade
(Alliance News) - Indivior PLC on Wednesday said it aims to list on the Nasdaq in spring 2023 as it expects its injection Sublocade to reach peak annu...
Indivior raises guidance for peak net revenue potential of Sublocade asset
(Sharecast News) - Pharmaceuticals business Indivior upgraded guidance for the peak annual net revenue potential of its Sublocade asset on Wednesday a...
Indivior buys Opiant creating "comprehensive" treatment platform
(Alliance News) - Indivior PLC on Monday announced the acquisition of Opiant Pharmaceuticals Inc for around USD145 million.
Indivior to buy US overdose treatment firm Opiant for $145m
(Sharecast News) - UK-based drug company Indivior said it would pay $145m for Opiant Pharmaceuticals which produces treatments to overcome opioid addi...
Follow the stocks
